Vitreous substitutes

Expert Review of Ophthalmology

Volumn 3, Issue 2, 2008, Pages 211-218

  Foster, William Joseph ^a,b  

^a University of Houston   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Polymer; Retina; Retinal detachment; Tissue engineering; Vitrectomy; Vitreous substitute

Indexed keywords

ACRYLIC ACID DERIVATIVE; BALANCED SALT SOLUTION; COLLAGEN; COLLAGEN TYPE 2; DEXAMETHASONE; FLUORINATED HYDROCARBON; FLUOROURACIL; GLYCOLIC ACID DERIVATIVE; HEPARIN; HYALURONIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; METHYLATED COLLAGEN; PERFLUOROPHENANTHRENE; PERFLUOROTRIPROPYLAMINE; POLY(2 HYDROXYETHYL ACRYLATE); POLYANION; POLYESTER; POLYMETHYL 3,3,3 TRIFLUOROPROPYLSILOXANE CO DIMETHYLSILOXANE; POLYMETHYLACRYLAMIDOGLYCOLATE METHYL ESTER; POLYVINYL ALCOHOL; POVIDONE; SEMIFLUORINATED ALKANE; SILICONE GEL; SILICONE OIL; SILOXANE; STEROID;

BODY POSITION; CATARACT; CLINICAL TRIAL; COLLAGEN DEFECT; EMULSION; EYE TOXICITY; GLAUCOMA; HUMAN; KERATOPATHY; LASER COAGULATION; MAGNETIC FIELD; MAGNETISM; NONHUMAN; OSMOSIS; OUTCOME ASSESSMENT; PIGMENT EPITHELIUM; RETINA DETACHMENT; RETINA MACULA HOLE; RETINA TEAR; RETINOPEXY; REVIEW; SCAR; SCLERA BUCKLING PROCEDURE; SURFACE TENSION; SURGICAL TECHNIQUE; TISSUE ENGINEERING; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY; VITREOUS BODY; VITREOUS FLUID SUBSTITUTE; VITREOUS HEMORRHAGE;

EID: 46949090463     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.3.2.211     Document Type: Review

References (89)

1. Machemer R, Buettner H, Norton EW, Parel JM. Vitrectomy: a pars plana approach. Trans. Am. Acad. Ophthalmol. Otolaryngol. 75(4), 813-820 (1971).
2. Rowe JA, Eric JC, Baratz KH et al. Retinal detachment in Olmsted County, Minnesota, 1976 through 1995. Ophthalmology 106, 154-159 (1999).
3. Wilkes SR, Beard CM, Kurland LT, Robertson DM, O'Fallon WM. The incidence of retinal detachment in Rochester, Minnesota, 1970-1978. Am. J. Ophthalmol. 94, 670-673 (1982).
4. Haimann MH, Burton TC, Brown CK. Epidemiology of retinal detachment. Arch. Opbthalmol. 100, 289-292 (1982).
5. Ünlü N, Kocaogbrevelan H, Acar MA, Sargin M, Aslan BS, Duman S. Outcome of complex retinal detachment surgery after silicone oil removal. Int. Ophthalmol. 25, 33-36 (2004).
6. Charles S. Vitreous microsurgery. Williams & Wilkins, Baltimore, USA (1981).
7. Olm J. Über die Behandlung der Netzhautablösung dutch operative Endeerung der Subretinalen Flüssigkeit und Einspritzung von Luft in den Glaskörper. Albrecht von Graefes Arch. Ophthalmol. 79, 442-465 (1911).
8. Peyman GA, Schulman JA. Vitreous Substitutes. Appleton & lange, CT, USA (1995).
9. Balazs EA. Fine structure and function of ocular tissues. The vitreous. Int. Ophthalmol. Clin. 13, 169-187 (1973).
10. Hogan MJ. The vitreous, its structure, and relation to the ciliary body and retina. proctor award lecture. Invest. Ophthalmol. 51, 418-445 (1963).
11. Sebag J, Balazs EA. Morphology and ultrastructure of human vitreous fibers. Invest. Ophthalmol. Vis. Sci. 30, 1867-1871 (1989).
12. Los LI, van der Worp RJ, van Luyn MJ, Hooymans JM. Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. Invest. Ophthalmol. Vis. Sci. 44, 2828-2833 (2003).
13. Wilkinson CP, Rice TA. In: Michels Retinal Detachment. (2nd Edition). Mosby, MO, USA (1997).
14. Foster WJ, Chou T. Physical mechanisms of gas and perfluron retinopexy and sub-retinal fluid displacement. Phys. Med. Biol. 49, 2989-2997 (2004).
15. Lincoff H, Kreissig I, Jakobiec F, Iwamoto T. Remodeling of the cryosurgical adhesion. Arch. Ophthalmol. 99, 1845-1849, (1981).
16. Chang TS, Pelzek CD, Nguyen RL, Purohit SS, Scott GF, Hay D. Inverted pneumatic retinopexy: a method of treating retinal detachments associated with inferior retinal breaks. Ophthalmology 110, 589-594 (2003).
17. Cibis PA, Becker B, Okun E, Canaan S. The use of liquid silicone in retinal detachment surgery. Arch. Ophthalmol. 68, 590-599 (1962).
18. Lai JC, Stinnett SS, McCuen BW. Comparison of silicone oil versus gas tamponade in the treatment of idiopathic full-thickness macular hole. Ophthalmology 110, 1170-1174 (2003).
19. Federman JA Schubert HD. Complications associated with the use of silicone oil in 150 eyes after retina-vitreous surgery. Ophthalmology 95, 870-876 (1988).
20. Scott IU, Flynn HW Jr, Murray TG, Smiddy WE, Davis JI, Feuer WJ. Outcomes of complex retinal detachment repair using 1000- vs 5000-centistoke silicone oil. Arch. Ophthalmol. 123, 473-478 (2005).
21. Majid MA, Hussin HM, Biswas S, Haynes RJ, Mayer EJ, Dick AD. Emulsification of Densiron-68 used in inferior retinal detachment surgery. Eye 22(1), 152-157 (2007).
22. Sandner D, Engelmann K. First experience with high-density silicone oil (Densiron) as an intraocular tamponade in complex retinal detachment. Graefes Arch. Clin. Exp. Ophthalmol. 244, 609-619 (2006).
23. Tognetto D, Minutola D, Sanguinetti G, Ravalico G. Anatomical and functional outcomes after heavy silicone oil tamponade in vitreoretinal surgery for complicated retinal detachment: a pilot study. Ophthalmology 112, 1574 (2005).
24. Rizzo S, Genovesi-Ebert F, Vento A, Cresti F, Di Bartolo E, Belting C. A new heavy silicone oil (HWS 46-3000) used as a prolonged internal tamponade agent in complicated vitreoretinal surgery: a pilot study. Retina 27, 613-620 (2007).
25. Theelen T, Tilanus MA, Klevering BJ. Intraocular inflammation following endotamponade with high-density silicone oil. Graefes Arch. Clin. Exp. Ophthalmol. 242, 617-620 (2004).
26. Chang S, Sparrow JR, Iwamoto T, Gershbein A, Ross R, Ortiz R. Experimental studies of tolerance to intravitreal perfluoro-N-octane liquid. Retina 11, 367-474 (1991).
27. Sparrow JR, Matthews GP, Iwamoto T, Ross R, Gershbein A, Chang S. Retinal tolerance to intravitreal perfluoroethylcyclohexane liquid in the rabbit. Retina 13, 56-62 (1993).
28. Velikay M, Wedrich A, Stolba U, Datlinger P, Li Y, Binder S. Experimental long-term vitreous replacement with purified and nonpurified perfluorodecalin. Am. J. Ophthalmol. 116, 565-570 (1993).
29. Rofail M, Lee LR. Perfluoro-N-octane as a postoperative vitreoretinal tamponade in the management of giant retinal tears. Retina 25, 897-901 (2005).
30. Sirimaharaj M, Balachandran C, Chan WC et al. Vitrectomy with short term postoperative tamponade using perfluorocarbon liquid for giant retinal tears. Br. J. Ophthalmol. 89, 1176-1179, (2005).
31. Chandrasekar S. Hydrodynamic and Hydromagnetic Stability. (Eds), Dover, New York, NY, USA (1981).
32. Stopa M, Lincoff A, Lincoff H. Analysis of forces acting upon submacular hemorrhage in pneumatic displacement. Retina 27, 370-374 (2007).
33. Heidenkummer HP, Kampik A, Thierfelder S. Experimental evaluation of in vitro stability of purified polydimethylsiloxanes (silicon oil) in viscosity ranges from 1000 to 5000 centistokes. Graefes Arch. Clin. Exp. Ophthalmol. 87, 226-228 (1991).
34. Bartov E, Pennarola F, Savion N et al. A quantitative in vitro model for silicon oil emulsification: role of blood constituents. Retina 12(3 Suppl.), S23-S27 (1992).
35. Guidry C. The role of Müller cells in fibrocontractive retinal disorders. Prog. Retinal Eye Res. 24, 75-86 (2005).
36. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog. Retinal Eye Res. 21, 127-144 (2002).
37. Sun JK, Arroyo.JG. Adjunctive therapies for proliferative vitreoretinopathy. Int. Ophthalmol. Clin. 44, 1-10 (2004).
38. Koerner F, Mertz A, Gloor B et al. Postoperative retinal fibrosis - a controlled clinical study of systemic steroid therapy. Graefes Arch. Clin. Exp. Ophthalmol. 90, 810-816 (1982).
39. Asaria RH, Kon CH, Bunce C et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 108, 1179-1183 (2001).
40. Borhani H, Peyman GA, Rahimy MH et al. Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Int. Ophthalmol. 19, 43-49 (1995).
41. The Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90, 121-125 (1983).
42. Williams RG, Chang S, Comaratta MR et al. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy? Graefes Arch. Clin. Exp. Ophthalmol. 234, 496-503 (1996).
43. Lewis H, Burke JM, Abrams GW et al. Perisilicon proliferation after vitrectomy for proliferative vitreoretinopathy. Ophthalmology 94, 583-591 (1988).
44. Ni C, Wang WJ, Albert DM et al. Intravitreous silicon injection: Histopathologic findings in a human eye after 12 years. Arch. Ophthalmol. 101, 1399-1401 (1986).
45. Honda Y, Ueno S, Miura M et al. Silicon oil particles trapped in the subretinal space: Complications aher substitution of the vitreous. Ophthalmologica 192, 1-5 (1986).
46. Kirchhof B, Tavakolian U, Paulmann H et al. Histopathological findings in eyes after silicon oil injection. Graefes Arch. Clin. Exp. Ophthalmol. 224, 34-37 (1986).
47. Shikishima H, Ohki K, Machi N et al. Effects and distribution of intravitreally or subretinally injected silicon oil identified in rabbit retina using osmium tetroxide method. Jpn. J. Ophthalmol. 36, 369-478 (1992).
48. Refojo MF, Leong FL, Chung H et al. Extraction of retinol and cholesterol by intraocular silicon oils. Ophthalmology 95, 614-618 (1988).
49. Suzuki M, Okada T, Takeuchi S et al. Effect of silicon oil on ocular tissues. Jpn J. Ophthalmol. 35, 282-291 (1990).
50. Pastor JC, Lopez MI, Saornil MA et al. Intravitreal silicon and fluorosilicone oils: Pathologic finding in rabbit eyes. Acta Ophthalmol. 70, 651-658 (1992).
51. Miyamoto K, Refojo MF, Tolentino FL et al. Fluorinated oils as experimental vitreous substitutes. Arch. Ophthalmol. 104, 1053-1056 (1986).
52. Chang S, Zimmerman NJ, Iwamoto T et al. Experimental vitreous replacement with perfluorotributylamine. Am. J. Ophthalmol. 103, 29-37 (1987).
53. Velikay M, Wedrich A. Stolba U et al. Experimental long-term vitreous replacement with purified and nonpurified perfluorodecalin. Am. J. Ophthalmol. 116, 565-570 (1993).
54. Fineberg E, Machemer R, Sullivan P et al. Sulfur hexafluoride in owl monkey vitreous cavity. Am. J. Ophthalmol. 79, 67-76 (1875).
55. Lincoff H, Mardirossian J, Lincoff A et al. Intravitreal longevity of three perfluorocarbon gases. Arch. Ophthalmol. 98, 1610-1611 (1980).
56. Leaver PKm Silicon-oil injection in the treatment of massive preretinal retraction In: New and Controversial Aspects of Vitreoretinal Surgery. McPherson A (Ed.). Mosby, MO, USA, 397-401 (1977).
57. Cockerham W, Schepens CL, Freeman HM. Silicon injection in retinal detachment. Mod. Probl, Ophthalmol. 8, 625-540 (1969).
58. Moisseiev J, Bartov E, Cahane M et al. Cataract extraction in eyes filled with silicon oil. Arch. Ophthalmol. 110, 1649-1651 (1992).
59. Grey RHB, Leaver PK. Results of silicone oil injection in massive preretinal retraction. Trans. Ophthalmol. Soc. UK 97, 238-241 (1977).
60. Ni C, Wang WJ, Alber DM et al. Intravitreous silicone injection: Histopathologic findings in a human eye after 12 years. Arch. Ophthalmol. 101, 1399-1401 (1983).
61. Leaver PK, Grey RH, Garner A. Complications following silicone-oil injection. Mod. Probl. Ophthalmol. 20, 290-294 (1981).
62. Alexandridis E, Daniel H. Results of silicon oil injection into the vitreous. Dev. Ophthalmol. 2, 24-27 (1981).
63. Al-Jazzaf AM, Netland PA, Charles S. Incidence and management of elevated intraccular pressure after silicone oil injection. J. Glaucoma 14, 40-46 (2005).
64. McCuen BW II, Dejuan E Jr, Landers MB III et al. Silicone oil in vitreoretinal surgery: II. Results and complications. Retina 5, 198-205 (1985).
65. Gao R, Neubauer L, Tang S et al. Silicone oil in the anterior chamber. Graefes Arch. Clin. Exp. Ophthalmol. 227, 106-109 (1989).
66. Casswell AG, Gregor ZJ. Silicon oil removal: I. The effect of silicon oil on the cornea. Br. J. Ophthalmol. 110, 1649-1651 (1992).
67. Beekhuis WH, van Rij G, Zivojnovic R. Silicon oil keratopathy: indications for keratoplasty. Br. J. Ophthalmol. 69, 247-253 (1985).
68. Setala K, Ruusuvaara P, Punnonen E et al. Changes in corneal endothelium after treatment of retinal detachment with intraocular silicon oil. Acta Ophthalmol. 67, 37-42 (1989).
69. Colthurst MJ, Williams RL, Hiscott PS, Grierson I. Biomaterials Used in the posterior segment of the eye. Biomaterials 21, 649-665 (2000).
70. Peyman GA, Conway MD, Soike KF, Clark LC. Long-Term vitreous replacement in primates with intravitreal vitreon or vitreon plus silicone. Ophthalmic Surg. 22, 657-664 (1991).
71. Bryan JS, Friedman SM, Marries RN, Margo CE. Experimental Vitreous Replacement with Perfluorotri-N-propylamine. Arch. Ophihalmol. 112, 1098-1102 (1994).
72. Doi M, Refojo MF. Histopathology of rabbit eyes with silicone-fluorosilicone copolymer oil as six months internal retinal tamponade. Exp. Eye Res. 61, 469-478 (1995).
73. Chan IM, Tolentino FI, Refojo MG, Fournier G, Albert DM. Vitreous substitute experimental studies and review. Retina 4, 51-59 (1984).
74. Zeana D, Becker J, Kuckelkorn R, Kirchhof B. Perfluorohexyloctane as a long-term vitreous tamponade in the experimental animal. Experimental perfluorohexyloctane substitution. Int. Ophthalmol. 23, 17-24 (1999).
75. Peyman GA, Conway MD, Karacorlu M et al. Evaluation of silicone gel as a long-term vitreous substitute in non-human primates. Ophthalmic Surg. 23, 811-817 (1992).
76. Liang Cp, Peyman GA, Serracarbassa P, Calixto N, Chow AA, Rao P. An evaluation of methylated collagen as a substitute for vitreous and aqueous humor. Int. Ophthalmol. 22, 13-18 (1998).
77. Nakagawa M, Tanaka M, Miyata T. Evaluation of collagen gel and hyaluronic acid as vitreous substitutes. Ophthalmic Res. 29, 409-420 (1997).
78. Fernandez-Vigo J, Refojo MF, Verstraeten T. Evaluation of a viscoelastic solution of hydroxypropyl methylcellulose as a potential vitreous substitute. Retina 10, 148-152 (1990).
79. Yamauchi A. Synthetic vitreous body of PVA hydrogel. In: Polymer Gels. DeRossi D, Kajiwara K, Osada Y, Yamauchi A (Eds). Plenum Press, NY, USA, 127-134 (1991).
80. Chirila TV, Sharp C, Moore SR et al. Synthetic hydrogel as an artificial vitreous body: a one-year animal study of its effects on the retina. Cells Mater. 5, 83-96 (1995).
81. Hong Y, Chirila TV, Vijayasekaran S et al. Crosslinked poly(1-vinyl-2-pyrrolidinone) as a vitreous substitute. J. Biomed. Mat. Res. 30, 441-448 (1996).
82. Phillips JP, Li C, Dailey JP, Riffle JS. Synthesis of silicone magnetic fluids for use in eye surgery. J. Mag. Mag. Mater. 194, 140-148 (1999).
83. Vadala TP, Goff JD, Zhang Q, Dailey JP, Riffle JS. Polysiloxane magnetic fluids for use in eye surgery. Proceedings of the 29th Annual Meeting of the Adhesion Society. Jacksonville, FL, USA, 19-22 February 2006.
84. Foster WJ, Aliyar HA, Hamilton P, Ravi N. Internal osmotic pressure as a mechanism of retinal attachment in a vitreous substitute. J. Bioact. Compat. Pol. 21, 221-235 (2006).
85. Flanagan LA, Ju YE, Marg B, Osterfield M, Janmey PA. Neurite branching on deformable substrates. Neuroreport 13, 2411-2415 (2002).
86. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell 126, 677-89 (2006).
87. Foster WJ, Janmey PA, Flannagan LA, Ravi N. Proliferative vitreoretinopathy inhibition utilizing a nanostructured vitreous substitute. Presented at: Meeting of the American Society of Retina Specialists. Palm Springs, CA, USA, November 30-December 5, 2007.
88. Foster WJ, Janmey PA, Flanagan LA, Sawyer ES. A novel, formed vitreous substitute to repair battlefield ocular trauma and complex retinal detachments: a mechanical mechanism of PVR ("scar tissue") inhibition. Presenter The Advanced Technology Applications for Combat Casualty Care (ATACCC) Meeting. Saint Pete Beach, FL, USA 13-15 August, 2007.
89. Foster WJ, Janmey PA, Flanagan LA. A mechanical mechanism of proliferative vitreoretinopathy inhibition in vitreous substitutes. Investig. Ophthalmol. Vis. Sci. 47, 3823 (2006).